Element Biosciences
PrivateLast Round
Series E
Jun 9, 2026
Est. Valuation
$1.03B
Total Funding Raised
$888.41M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Element Biosciences is a biotechnology company that develops modular and high-performing DNA sequencing platforms designed to enhance research and diagnostics by providing quality data and workflow flexibility.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Element Biosciences Comparables
Compare Element Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ultima Genomics | 87% | |
| Singular Genomics | 84% | |
| Axbio | 81% |
For institutional investors. Book with your work email.
Element Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Jun 9, 2026 | ||||
| Series D | Jul 11, 2024 | ||||
| Series C | Jun 29, 2021 | ||||
| Series B Extension | Jun 26, 2020 | ||||
| Series B | Jan 9, 2020 | ||||
Series A | Jun 18, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Element Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| RA Capital Management | Series B Extension, Series B, Series C |
| Fusion Fund | Series D |
| Fidelity Management & Research Company | Series D, Series C, Series B |
| Fidelity Investments | Series D |
| Morgan Stanley | Series C |
| Logos Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 33% MoM, reaching 26K.
- Jun 9, 2026
$175M round led by Samsung Electronics
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 29, 2026
Element Biosciences commercially launches AVITI Dx, its first CE-marked in vitro diagnostic sequencing platform under the EU IVDR, across ten EU countries on Oct 29th '26.
- launchesOct 21, 2026
Element Biosciences launches the VITARI benchtop sequencer and Cytos single-cell platform at the opening event of a global roadshow in Seoul, South Korea, with VITARI available for pre-order and shipments due by the end of 2026.
For institutional investors. Book with your work email.
Element Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Element Biosciences's valuation, stock price, and market status.
Is Element Biosciences a public or private company?
Element Biosciences is a private company.
What is the current stock price of Element Biosciences?
Element Biosciences is a private company, so its shares have no public market price. Caplight tracks Element Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Element Biosciences worth (valuation)?
Element Biosciences's valuation is estimated at $1.0B based on funding round data.
Can I buy Element Biosciences stock?
Element Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Element Biosciences's last funding round?
Element Biosciences's most recent funding round was Series E on June 9, 2026.
Who are the main investors in Element Biosciences?
Key investors in Element Biosciences include Fidelity Management & Research Company, Morgan Stanley, Foresite Capital, T. Rowe Price, JSCapital.
Will Element Biosciences IPO soon?
No public IPO plans have been announced for Element Biosciences.
How can I track Element Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Element Biosciences's shares on secondary markets.